

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number
WO 01/00825 A2

- (51) International Patent Classification⁷: C12N 15/12, (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/US00/17375
- (22) International Filing Date: 22 June 2000 (22.06.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/141,753 30 June 1999 (30.06.1999) US
- (71) Applicant: CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US).
- (72) Inventors: DUHL, David; 2720 Camino Lenada, Oakland, CA 94611 (US). GORMAN, Susan, Wilkie; #5, 1139 Yale Street, Santa Monica, CA 90403 (US).
- (74) Agents: BLACKBURN, Robert, P. et al.; Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608-2916 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/00825 A2

(54) Title: HUMAN CHROMOSOME 15 AND 16 BARDET-BIEDL SYNDROME POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE

(57) Abstract: Amino acid and nucleic acid sequences of Bardet-Biedl Syndrome Region (BBSR) that map to human chromosome 15 or 16 are disclosed. Compositions and methods related to the genes and proteins are useful in the study, diagnosis and treatment of a variety of diseases including BBS and related conditions including obesity, retinal degeneration, and disorders affecting the nervous system, the heart, the kidneys, and the like. Compositions include those comprising BBSR polypeptides and derivatives thereof, nucleotide sequences, expression cassettes, vectors, transformed cells and antibodies. Methods include those for expression and detection of BBSR nucleotides and polypeptides.

HUMAN CHROMOSOME 15 AND 16 BARDET-BIEDL SYNDROME POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE

TECHNICAL FIELD

This invention relates to the identification and recombinant expression of
5 human chromosome 15 and 16 Bardet-Biedl Syndrome Region (BBSR) proteins.

BACKGROUND OF THE INVENTION

Bardet-Biedl Syndrome (BBS) is a clinically and genetically
heterogeneous autosomal recessive disorder characterized by obesity, polydactyly,
hypogenitalism, retinal degeneration, mental retardation and heart and kidney
10 abnormalities.

Elbedour et al. (1994) *Am. J. Med. Genet.* 52(2):164-169 have reported
hypertrophy of the interventricular septum and dilated cardiomyopathy, in addition to
other previously reported congenital heart defects associated with BBS.

BBS has been mapped to loci on several human chromosomes including
15 chromosomes 3, 11, 15 and 16. These loci include the 3p12, 11q13, 15q22 and the
16q21 chromosomal sites; also referred to as the BBS3, BBS1, BBS4 and BBS2 loci,
respectively. (Bruford et al. (1997) *Genomics* 41(1):93-9; Leppert et al. (1994) *Nature*
Genet. 7:108-112; Carmi et al. (1995) *Hum. Mol. Genet.* 4:9-13; Kwitek-Black et al.
(1993) *Nature Genet.* 5:392-396; Sheffield et al. (1994) *Hum. Mol. Genet.* 3:1331-1335;
20 Beales et al. (1997) *J. Med. Genet.* 34(2):92-8.).

Attempts to associate particular phenotypes with particular BBS loci
have been reported. For example, Beales et al. (1997) *J. Med. Genet.* 34(2):92-8,
reported that affected subjects linked to the BBS2 and 4 loci were significantly shorter
than their parents, while those linked to the BBS1 locus were taller, indicating possible
25 role for various BBS genes in influencing growth characteristics such as height. Carmi
et al. (1995) *Hum. Mol. Genet.* 4:9-13, reported that BBS3 is associated with
polydactyly of all four limbs while BBS4 polydactyly is mostly confined to the hands

and that BBS4 is associated with early-onset morbid obesity, while BBS2 appears as the leanest form of BBS.

Reports of specific genes involving BBS loci are sparse. Zhu et al. (1998) *Hum. Genet.* 193(6):674-680 have reported identification of a human p70s6
5 kinase with a possible role in BBS1 which is mapped to 11q13. Hoang et al. (1998) *Genomics*:52 (2): 219-222, have reported cloning of a C-terminal kinesin (KIFC3) that maps to human 16q13-q21 within the BBS2 region.

BBS and associated disorders have many serious effects on humans. There is a need for identifying compositions that are useful in diagnosis and treatment
10 of such disorders.

SUMMARY OF THE INVENTION

The present invention discloses amino acid and nucleic acid sequences of human chromosome 15 and 16 Bardet-Biedl Syndrome Region (BBSR). The corresponding genes are referred to as Gene X, plasmolipin-like protein (PLP), ORPH-
15 PPAR (PPAR), NT2 neuronal precursor-like (NTPL), and a seven transmembrane domain protein. The new genes and proteins are useful in the study, diagnosis and treatment of a variety of diseases including BBS and related conditions. Other indications that can be treated by the BBSR nucleotides, proteins and/or BBSR polypeptides, or agonists or antagonists include obesity, retinal degeneration, and
20 disorders affecting the central nervous system, the heart, the kidneys, and the like.

Compositions and methods for expressing and using BBSR nucleotides and proteins are provided. The compositions comprise BBSR polypeptides and derivatives thereof, nucleotide sequences, expression cassettes, vectors, transformed cells and antibodies. Methods for the expression and detection of BBSR nucleotides
25 and polypeptides and compositions for the treatment of BBS related conditions are provided.

The invention further provides (a) a polynucleotide encoding amino acids

from about 1 or about 2 to about 254 of SEQ ID NO:2; (b) a polynucleotide encoding amino acids from about 1 or about 2 to about 218 of SEQ ID NO:4; (c) a polynucleotide encoding amino acids from about 1 or about 2 to about 297 of SEQ ID NO:6; (d) a polynucleotide encoding amino acids from about 1 or about 2 to about 513 of SEQ ID NO:9; (e) a polynucleotide comprising SEQ ID NO:7; (f) the polynucleotide complement of the polynucleotide of any one of (a) through (e); and (g) a polynucleotide at least 90% identical to the polynucleotide of any one of (a) through (e).

The invention still further provides a method of making a recombinant vector comprising inserting a nucleic acid molecule of (a) through (g) into a vector in operable linkage to a promoter; a recombinant vector produced thereby; a method of making a recombinant host cell comprising introducing the recombinant vector into a host cell; a recombinant host cell produced by this method; and a recombinant method of producing a polypeptide, comprising culturing the recombinant host cell under conditions such that the polypeptide is expressed, and recovering the polypeptide.

The invention also provides an isolated polypeptide comprising an amino acid sequence from (a) about 1 or about 2 to about 254 of SEQ ID NO:2; (b) about 1 or about 2 to about 218 of SEQ ID NO:4; (c) about 1 or about 2 to about 297 of SEQ ID NO:6; or (d) about 1 or about 2 to about 513 of SEQ ID NO:9; an isolated polypeptide wherein, except for at least one conservative amino acid substitution, the polypeptide has an amino acid sequence of one of (a) through (d); and an isolated polypeptide comprising amino acids at least 95% identical to an amino acid sequence of one of (a) through (d).

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 provides the nucleotide and amino acid sequence of the human Gene X protein (SEQ ID NO:1, 2).

Figure 2 provides the nucleotide and amino acid sequence of the human PLP cDNA (SEQ ID NO:3, 4).

Figure 3 provides the nucleotide and amino acid sequence of the human PPAR cDNA (SEQ ID NO:5, 6).

Figure 4 provides the nucleotide sequence of the human NTPL cDNA (SEQ ID NO:7).

5 Figure 5 provides the nucleotide and amino acid sequence of a human seven transmembrane receptor protein (SEQ ID NO:8, 9).

DETAILED DESCRIPTION OF THE INVENTION

Compositions and methods for expressing and using BBSR nucleotides, proteins and polypeptides are provided. The compositions and methods find use in the
10 treatment of BBS and BBS-related conditions including obesity, retinal degeneration, mental retardation, central nervous system disorders, heart and kidney abnormalities, and the like. More particularly, new genes, and polypeptides encoded by the genes have been identified that are useful in the treatment of these and a variety of other conditions. The human BBSR polypeptides and cDNAs are provided in Figures 1-5 (SEQ ID NO:
15 1-9).

The compositions and methods of the invention can be used for the treatment and diagnosis of BBS, a disorder having a clinical manifestation of BBS, or any disorder that shares a clinical manifestation of BBS, so long such disorders can be diagnosed and/or treated by the methods and compositions of the invention, in a
20 clinically or experimentally determinable manner.

The invention provides isolated nucleic acid molecules comprising a nucleotide sequence encoding the BBSR polypeptides whose amino acid sequences are provided in Figures 1-5, or a variant or fragment of the polypeptides. Furthermore, polynucleotides comprising antisense sequences for BBSR proteins are provided.

25 The BBSR sequences provided in Figures 1-5 (SEQ ID NO:1-9) correspond to Gene X, plasmolipin-like protein (PLP), ORPH-PPAR (PPAR), NT2 neuronal precursor-like protein (NTPL), and 7-transmembrane receptor protein, respectively.

For Gene X, the invention provides a 2850 bp cDNA (SEQ ID NO:1), which was isolated from human brain frontal cortex, and encodes an open reading frame of 762 bp (encompassing bases 214-976). Northern analysis showed that the transcript of Gene X is expressed in brain (cerebellum, cerebral cortex, medulla, spinal cord, occipital lobe, frontal lobe, temporal lobe and putamen), heart, skeletal muscle, spleen, testis, pancreas. Very low expression was detected in thymus, ovary, small intestine, colon, peripheral blood leukocytes, placenta, lung, liver and kidney. The gene is located on chromosome 16.

For plasmolipin-like protein, the invention provides a 1516 bp cDNA (SEQ ID NO:3) from human brain that encodes an open reading frame of 545 bp (encompassing bases 210-755). At the nucleotide level, this sequence contains about 85% identity with human NTII-11 nerve protein and rat plasmolipin. At the amino acid level the sequence has about 89% identity with rat plasmolipin and with NTII-11. The transcript of this novel gene is expressed in brain, kidney, lung, pancreas, spleen, prostate, heart, testis, small intestine, liver, colon, skeletal muscle, placenta and ovary, but is not visible on Northern blots of thymus and peripheral blood leukocytes.

Plasmolipin is a proteolipid found on the apical surface of tubular epithelial cells of the kidney and in myelinated tracts of the brain. Addition of plasmolipin to lipid bilayers induces the formation of ion channels, which are voltage-dependent and K(+)-selective. The PLP nucleic acids and proteins of the invention find use in membrane trafficking, gap junction formation, ion transport and cell volume regulation (U.S. Patent No. 5,843,714). In addition, plasmolipin transcript levels correlate with myelination of nerve cells, as crushed nerves undergoing regeneration displayed increased transcript levels.

Proteins involved in ion transport play vital roles in excitable cells and tissues, including muscle and nerve, in which ionic changes are primarily associated with electrophysiological responses such as generation of action potentials and/or excitation-contraction coupling. It is also known that proteins involved in ion transport play important roles in tissues in which ion transport is a primary physiological function, such as kidney.

The novel plasmolipin-like gene of this invention (PLP) is implicated in Bardet-Biedl syndrome (BBS) since it falls within the region containing the chromosome 16 BBS gene. The expression pattern of the PLP gene of the invention is consistent with the pleiotropic manifestations of BBS. Furthermore, since plasmolipin is involved in ion transport and myelination, the PLP sequences of the invention may be involved in the health and proper maintenance of nerve cells/fibers, and are particularly useful for diagnosis and treatment of disorders associated with the nervous system, including central and peripheral nervous systems. Examples of such disorders include but are not limited to BBS, Laurence-Moon-Bardet-Biedl syndrome, leukodystrophy, multiple sclerosis, Charcot-Marie-Tooth neuropathy type 1a, pressure neuropathy HNPP and Dejarine-Sottas disease.

For the new transcription factor, the invention provides a 2177 bp cDNA (SEQ ID NO:5) from human retina that encodes an open reading frame of 891 bp (encompassing bases 167-1057). The transcript of the transcription factor gene of the invention appeared ~1.5 kb on Northern and was expressed in brain (cerebellum, cerebral cortex, medulla, spinal cord, occipital lobe, frontal lobe, temporal lobe and putamen), heart, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood leukocytes. The transcript contains an open reading frame of 891 bp encompassing bases 167-1057 and predicts a protein of 297 amino acids.

The sequence exhibited some homology to an apolipoprotein A1 regulatory protein. Apo A1 expression is significant in cholesterol metabolism and atherosclerosis, particularly in light of the role of apo A1 in the reverse transport of cholesterol from peripheral tissues such as coronary arteries to the liver, the primary site of cholesterol metabolism for excretion. The sequences of the invention are particularly useful for the diagnosis and treatment of disorders associated with cholesterol homeostasis, for example, but not limited to obesity, atherosclerosis, and the like. Furthermore, the expression pattern of the gene of the invention is consistent with the pleiotropic manifestations of BBS involving obesity and cardiac disorders. It is

recognized that the sequences of the invention may be used to modulate cholesterol metabolism.

For the NT2 neuronal precursor-like clone (SEQ ID NO:7), the invention provides an isolated 214 base pair fragment located on BAC 17354. Northern blots
5 utilizing a 126 base pair probe corresponding to this fragment identified a transcript of about 2.3 kb that was present in brain (cerebellum, cerebral cortex, medulla, spinal cord, occipital lobe, frontal lobe, temporal lobe and putamen), heart, placenta, lung, liver skeletal muscle, kidney, pancreas, spleen, prostate, ovary, small intestine, colon, and peripheral blood leukocytes. A slightly larger transcript, about 2.4 kb, was present in
10 testis and no expression appeared in thymus RNA.

For human chromosome 16 seven transmembrane receptor protein, the invention provides a 3686 bp cDNA fragment (SEQ ID NO:8) from human brain (frontal cortex) that encodes an open reading frame of 1539 bp (encompassing bases 658-2193). This gene is located on human chromosome 16. Hydrophobicity analysis
15 indicates 7 membrane spanning regions. On Northern blots, this novel gene shows a transcript of ~4.4 kb that is expressed in brain (cerebellum, cerebral cortex, medulla, spinal cord, occipital lobe, frontal lobe, temporal lobe and putamen), heart, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes. A less abundant transcript of
20 ~6.2 is also present in all the tissues listed above. However, the ratio of expression of the two transcripts varied from tissue to tissue. For example, in heart the 4.4 kb transcript appeared to be expressed 10X more than the ~6.2 kb transcript, but in brain this ratio was closer to 50X. The transcript encodes a minimum of 10 exons.

This gene may relate to Bardet-Biedl syndrome since it falls within the
25 region containing the chromosome 16 BBS gene. The 7-transmembrane domain gene can be used to develop drug treatments and therapies for obesity and retinal degeneration.

Polypeptides of the invention encompass the sequences set forth herein as well as derivatives, analogs and variants thereof. Unless otherwise indicated,
30 variants include substantially homologous proteins having at least about 60-65%,

typically at least about 70-75%, more typically at least about 80-85%, and most typically at least about 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% or more homology to one of SEQ ID NO:2, 4, 6 or 9. It is recognized that amino acid substitutions may be made, particularly conservative substitutions. *See*, Bowie et al. (1990) *Science* 5 247:1306-1310. A variant polypeptide can differ in amino acid sequence by one or more substitutions, deletions, insertions, inversions, fusions and truncations or a combination of any of these. Variants can be naturally-occurring or can be made by recombinant means or chemical synthesis. Variant polypeptides may be fully functional or lack function in one or more activities.

10 Amino acids in the protein that are essential for function can be identified by site-directed mutagenesis, alanine-scanning mutagenesis (Cunningham et al. (1989) *Science* 244:1081-1085), etc. The resulting mutant molecules are then tested for biological activity. Critical sites for receptor binding can be determined. *See*, for example, Smith et al. (1992) *J. Mol. Biol.* 224:899-904; de Vos et al. (1992) *Science* 15 255:306-312.

Another aspect of the invention is a chimeric polypeptide comprising a BBSR polypeptide, or fragment thereof and a polypeptide of interest. Similarly, the invention provides a chimeric polypeptide comprising a BBSR polypeptide, or fragment thereof, fused to a polypeptide of interest. Nucleotide sequences encoding chimeric 20 BBSR proteins and polypeptides are also provided.

Yet another object of the invention is to provide polynucleotides that encode the mutants, fragments, and derivatives, as well as the native BBSR proteins and polypeptides. These polynucleotides can be operably linked to heterologous promoters to form expression cassettes. The expression cassettes can be introduced into suitable 25 host cells for expression of BBSR proteins and/or polypeptides and derivatives thereof.

The invention encompasses polynucleotide sequences having at least 65% sequence identity to SEQ ID NO:1, 3, 5, 7, or 8 as determined using algorithms known to those of ordinary skill in the art. A preferred but non-limiting example of a suitable algorithm is the Smith-Waterman homology search algorithm as implemented 30 in MSPRCH program (Oxford Molecular) using an affine gap search with the following

search parameters: gap open penalty of 12, and gap extension penalty of 1. For the purpose of encoding polypeptides that vary in respect to SEQ ID NO:2, 4, 6, or 9 as described herein, the polypeptide encoded by the polynucleotides having the percent homology described above is tested for retention of biological characteristics of the native protein, and significant variation from the sequence of SEQ ID NO:1, 3, 5, or 8 may be permitted as long as the protein retains such characteristics. However, if the polynucleotide variant is used as a probe for, for example, mRNA corresponding to SEQ ID NO:1, 3, 5, 7, or 8, then percent homology should be maximized to allow specific detection of the mRNA.

10 Another object of the invention is to provide a transformed cell transiently expressing or having stably incorporated into its genome an expression vector comprising a promoter operably linked to a nucleotide sequence encoding a BBSR protein or polypeptide, or a fragment, derivative, mutant or fusion thereof.

15 The invention further provides methods for treating BBSR protein modulated disorders, including but not limited to Bardet-Biedl Syndrome, retinal degeneration including retinitis pigmentosa, obesity, mental retardation, renal abnormalities, diabetes and cardiovascular abnormalities. The methods comprise administering a therapeutically effective amount of a BBSR protein or polypeptide, or a derivative thereof to a subject in need of such treatment. In still another aspect, the invention provides a composition comprising BBSR protein or polypeptide or an active derivative thereof, and a pharmaceutically acceptable carrier.

20 The compositions of the invention comprise amino acid and nucleotide sequences for BBSR proteins. Such compositions have several uses including diagnosis and treatment of other BBSR protein-modulated disorders.

25 "BBSR protein-modulated disorders" and "BBSR protein modulated-disorders" include BBS and its various clinical manifestations including but not limited to obesity, hypogenitalism, retinal degeneration, retinis pigmentosa, polydactyly, brachydactyly, syndactyly, mental retardation, cardiovascular and renal abnormalities, and the like.

BBSR protein-modulated disorders and BBSR protein modulated-disorders also include disorders other than BBS which include a clinical manifestation associated with BBS. For example, several human diseases exist which manifest an obesity phenotype, including but not limited to Ahlstrom syndrome, polycystic ovarian disease, Usher's, Carpenter, Prader Willi, Cohen, and Morgagni-Stewart-Monell Syndromes.

Other Examples include, in addition to BBS, other human diseases characterized by retinal degeneration including, without limitation, Bassen-Kornzweig syndrome (abetalipoproteinemia), Best disease (vitelliform dystrophy), choroidemia, gyrate atrophy, congenital amaurosis, Refsum syndrome, Stargardt disease and Usher syndrome. Other retinopathies that may benefit from administration of the compositions of the invention include age-related macular degeneration (dry and wet forms), diabetic retinopathy, peripheral vitreoretinopathies, photic retinopathies, surgery-induced retinopathies, viral retinopathies (such as HIV retinopathy related to AIDS), ischemic retinopathies, retinal detachment and traumatic retinopathy retinal

The methods and compositions of the invention can be used for the treatment and diagnosis of BBS, a disorder having a clinical manifestation of BBS, or any disorder that shares a clinical manifestation of BBS, so long such disorders can be diagnosed and/or treated by the methods and compositions of the invention, in a clinically or experimentally determinable manner.

"Stringency" refers to conditions in a hybridization reaction that favor association of very similar sequences over sequences that differ. Factors affecting the stringency of hybridization are well known to those skilled in the art and are discussed in Sambrook et al., *Molecular Cloning: A Laboratory Manual, Second Edition*, Volume 2, Chapter 9, at page 9.50.

In general, convenient hybridization temperatures in the presence of 50% formamide are 42°C for a probe with is 95% to 100% homologous to the target fragment, 37°C for 90% to 95% homology, and 32°C for 85% to 90% homology. For lower homologies, formamide content should be lowered and temperature adjusted accordingly, using the equation above. If the homology between the probe and the

target fragment are not known, the simplest approach is to start with both hybridization and wash conditions, which are nonstringent. If nonspecific bands or high background are observed after autoradiography, the filter can be washed at high stringency and reexposed. If the time required for exposure makes this approach impractical, several hybridization and/or washing stringencies should be tested in parallel.

Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (*e.g.*, 10 to 50 nucleotides) and at least about 60°C for long probes (*e.g.*, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37°C, and a wash in 1X to 2X SSC (20X SSC = 3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55°C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.5X to 1X SSC at 55 to 60°C. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.1X SSC at 60 to 65°C.

A composition containing A is "substantially free of" B when at least about 85% by weight of the total A+B in the composition is A. Preferably, A comprises at least about 90% by weight of the total of A+B in the composition, more preferably at least about 95% or even 99% by weight.

Nucleic Acid BBSR Protein Probe Assays

mRNA levels in different cell types can be detected with nucleic acid probe assays. For example, PCR, branched DNA probe assays, or blotting techniques utilizing nucleic acid probes substantially identical or complementary to SEQ ID NO:1, 3, 5, 7, or 8 can determine the presence of BBSR protein cDNA or mRNA.

For genomic analysis or detection of denatured DNA, the nucleic acid probes will hybridize to a nucleotide sequence encoding the amino acid sequence shown

in SEQ ID NO:2, 4, 6, or 9, or the complement of a sequence encoding SEQ ID NO:1, 3, 5, 7, or 8. Though many different nucleotide sequences will encode the amino acid sequences, SEQ ID NO:2, 4, 6, or 9 is preferred because it is the actual sequence expressed in the human cells as disclosed herein. For single-stranded cDNA detection, the nucleic acid probe will hybridize to the complement of a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:2, 4, 6, or 9 or to a complement of SEQ ID NO:1, 3, 5, 7, or 8. For mRNA detection, the nucleic acid probe will hybridize to SEQ ID NO:1, 3, 5, 7, or 8 or to a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:2, 4, 6, or 9. The nucleic acid probe sequences need not be identical to SEQ ID NO:1, 3, 5, 7, or 8 or complements thereof.

Probes are typically at least about 15 to 20 nucleotides, more preferably at least about 30 nucleotides. The probes may be produced by synthetic procedures, such as the triester method of Matteucci et al. (1981) *J. Am. Chem. Soc.* 103:3185, or according to Urdea et al. (1983) *Proc. Natl. Acad. Sci. USA* 80:7461, or using commercially available automated oligonucleotide synthesizers. One example of a nucleotide hybridization assay is described in Urdea et al. PCT WO92/02526 and Urdea et al. U.S. Patent No. 5,124,246, herein incorporated by reference. Other methods of hybridization and detection are known to those skilled in the art.

Alternatively, the Polymerase Chain Reaction (PCR) is another well-known means for detecting small amounts of target nucleic acids. The assay is described in Mullis et al. (1987) *Meth. Enzymol.* 155:335-350; U.S. Patent No. 4,683,195; and U.S. Patent No. 4,683,202, incorporated herein by reference. Also, mRNA, cDNA and genomic DNA can be detected by traditional blotting techniques described in Sambrook et al. (1989) *Molecular Cloning: A Laboratory Manual* (New York, Cold Spring Harbor Laboratory).

BBSR Proteins

By "BBSR proteins" is meant the proteins and polypeptides encoded by SEQ ID NO: 1, 3, 5, 7 and 8, preferably the polypeptides having the amino acid sequence of SEQ ID NO: 2, 4, 6 or 9.

Reference to the individual BBSR proteins disclosed herein is intended to be construed to include BBSR proteins of any origin which are substantially homologous to and which are biologically equivalent to the BBSR proteins characterized and described herein. Such substantially homologous proteins may be native to any tissue or species and, similarly, biological activity can be characterized in any of a number of biological assay systems.

The term "biologically equivalent" is intended to mean that the compositions of the present invention are capable of demonstrating some or all of the same biological properties in a similar fashion, not necessarily to the same degree as the BBSR as described herein or recombinantly produced human BBSR of the invention.

By "substantially homologous" it is meant that the degree of homology of human BBSR protein to BBSR protein from any species is greater than that between a BBSR of the invention and any previously described corresponding BBSR protein.

Sequence identity or percent identity is intended to mean the percentage of same residues between two sequences, referenced to human BBSR protein when determining percent identity with non-human BBSR protein, referenced to BBSR protein when determining percent identity with non-BBSR proteins, when the two sequences are aligned using the Clustal method (Higgins et al., *Cabios* 8:189-191 (1992)) of multiple sequence alignment in the Lasergene biocomputing software (DNASTAR, INC, Madison, WI). In this method, multiple alignments are carried out in a progressive manner, in which larger and larger alignment groups are assembled using similarity scores calculated from a series of pairwise alignments. Optimal sequence alignments are obtained by finding the maximum alignment score, which is the average of all scores between the separate residues in the alignment, determined from a residue weight table representing the probability of a given amino acid change occurring in two related proteins over a given evolutionary interval. Penalties for opening and lengthening gaps in the alignment contribute to the score. The default parameters used with this program are as follows: gap penalty for multiple alignment=10; gap length penalty for multiple alignment=10; k-tuple value in pairwise alignment=1; gap penalty in pairwise alignment=3; window value in pairwise alignment=5; diagonals saved in

pairwise alignment=5. The residue weight table used for the alignment program is PAM250 (Dayhoff et al., in *Atlas of Protein Sequence and Structure*, Dayhoff, Ed., NDRF, Washington, Vol. 5, suppl. 3, p. 345, 1978).

Percent conservation is calculated from the above alignment by adding
5 the percentage of identical residues to the percentage of positions at which the two residues represent a conservative substitution (defined as having a log odds value of greater than or equal to 0.3 in the PAM250 residue weight table). Conservation is referenced to human BBSR protein when determining percent conservation with non-human BBSR protein, and referenced to BBSR when determining percent conservation
10 with non-BBSR protein. Conservative amino acid changes satisfying this requirement are: R-K; E-D, Y-F, L-M; V-I, Q-H.

The invention provides BBSR proteins or variants thereof having one or more polymers covalently attached to one or more reactive amino acid side chains. By way of example, not limitation, such polymers include polyethylene glycol (PEG),
15 which can be attached to one or more free cysteine sulfhydryl residues, thereby blocking the formation of disulfide bonds and aggregation when the protein is exposed to oxidizing conditions. In addition, pegylation of BBSR proteins and/or muteins is expected to provide such improved properties as increased half-life, solubility, and protease resistance. BBSR proteins and/or muteins may alternatively be modified by
20 the covalent addition of polymers to free amino groups such as the lysine epsilon or the N-terminal amino group. It will be apparent to one skilled in the art that the methods for assaying BBSR protein biochemical and/or biological activity may be employed in order to determine if modification of a particular amino acid residue affects the activity of the protein as desired.

25 It may be advantageous to improve the stability of BBSR protein by modifying one or more protease cleavage sites. Thus, the present invention provides BBSR protein variants in which one or more protease cleavage site has been altered by, for example, substitution of one or more amino acids at the cleavage site in order to create as BBSR protein variant with improved stability. Such improved protein
30 stability may be beneficial during protein production and/or therapeutic use.

Suitable protease cleavage sites for modification are well known in the art and likely will vary depending on the particular application contemplated. For example, typical substitutions would include replacement of lysines or arginines with other amino acids such as alanine. Preferred sites to substitute would include dibasic or tribasic sites within two residues of a proline. The loss of biological activity can be tested for the appropriate BBSR protein.

BBSR protein can also include hybrid and modified forms of BBSR protein including fusion proteins and BBSR fragments and hybrid and modified forms in which certain amino acids have been deleted or replaced and modifications such as where one or more amino acids have been changed to a modified amino acid or unusual amino acid and modifications such as glycosylations so long as the hybrid or modified form retains the biological activity of BBSR.

Fusion proteins comprising BBSR protein or a biologically active or antigenic fragment thereof can be produced using methods known in the art. Such fusion proteins can be used therapeutically or can be produced in order to simplify the isolation and purification procedures. Histidine residues can be incorporated to allow immobilized metal affinity chromatography purification. Residues EQKLISEEDL contain the antigenic determinant recognized by the myc monoclonal antibody and can be incorporated to allow myc monoclonal antibody-based affinity purification. A thrombin cleavage site can be incorporated to allow cleavage of the molecule at a chosen site; a preferred thrombin cleavage site is residues LVPRG. Purification of the molecule can be facilitated by incorporating a sequence, such as residues SAWRHPQFGG, which binds to paramagnetic streptavidin beads. Such embodiments are described in WO 97/25345, which is incorporated by reference.

The invention also includes fragments of BBSR proteins. Such fragments can be prepared from the protein by standard biochemical methods or by expressing a polynucleotide encoding the fragment. Also included with the scope of the invention are BBSR protein molecules that differ from native BBSR proteins by virtue of changes in biologically active sites.

Also included within the meaning of substantially homologous is any BBSR protein which may be isolated by virtue of cross-reactivity with antibodies to the BBSR described herein or whose encoding nucleotide sequences including genomic DNA, mRNA or cDNA may be isolated through hybridization with the complementary
5 sequence of genomic or subgenomic nucleotide sequences or cDNA of the BBSR protein herein or fragments thereof. It will also be appreciated by one skilled in the art that degenerate DNA sequences can encode human BBSR proteins and these are also intended to be included within the present invention as are allelic variants of BBSR proteins.

10 The DNA encoding BBSR proteins can be engineered to take advantage of preferred codon usage of host cells. Codon usage in *Pseudomonas aeruginosa* is described in, for example, West et al., *Nucleic Acids Res.* 11:9323-9335 (1988). Codon usage in *Saccharomyces cerevisiae* is described in, for example, Lloyd et al., *Nucleic Acids Res.* 20:5289-5295 (1992). Codon preference in *Corynebacteria* and a
15 comparison with *E. coli* preference is provided in Malubres et al., *Gene* 134:15-24 (1993). Codon usage in *Drosophila melanogaster* is described in, for example, Akashi, *Genetics* 136:927-935 (1994).

Any suitable expression vector may be employed to produce recombinant human BBSR proteins such as expression vectors for use in insect cells.
20 Baculovirus expression systems can also be employed.

The present invention includes nucleic acid sequences including sequences that encode human BBSR proteins. Also included within the scope of this invention are sequences that are substantially the same as the nucleic acid sequences encoding BBSR proteins. Such substantially the same sequences may, for example, be
25 substituted with codons more readily expressed in a given host cell such as *E. coli* according to well known and standard procedures. Such modified nucleic acid sequences are included within the scope of this invention.

Specific nucleic acid sequences can be modified by those skilled in the art and, thus, all nucleic acid sequences that code for the amino acid sequences of
30 BBSR proteins can likewise be so modified. The present invention thus also includes

nucleic acid sequence which will hybridize with all such nucleic acid sequences — or complements of the nucleic acid sequences where appropriate — and encode a polypeptide having the neuronal cell survival promoting activities disclosed herein. The present invention also includes nucleic acid sequences that encode polypeptides
5 that have neuronal cell survival promoting activity and that are recognized by antibodies that bind to BBSR proteins.

The present invention also encompasses vectors comprising expression regulatory elements operably linked to any of the nucleic acid sequences included within the scope of the invention. This invention also includes host cells of any variety
10 that have been transformed with vectors comprising expression regulatory elements operably linked to any of the nucleic acid sequences included within the scope of the present invention.

Expression of BBSR Protein and BBSR Polypeptides

Preferably, BBSR proteins and polypeptides are produced by
15 recombinantly engineered host cells. These host cells are constructed by the introduction of a expression vector comprising a promoter operably linked to a BBSR protein or polypeptide coding sequence.

Such coding sequences can be constructed by synthesizing the entire gene or by altering existing BBSR protein or polypeptide coding sequences. BBSR
20 polypeptides can be divided into four general categories: mutants, fragments, fusions, and the native BBSR polypeptides. The native BBSR polypeptides are those that occur in nature. The amino acid sequence of such polypeptides may vary slightly from SEQ ID NO:2, 4, 6, and 9. The native BBSR protein and BBSR polypeptide coding sequence can be selected based on the amino acid sequence shown in SEQ ID NO:2, 4,
25 6, and 9. For example, synthetic genes can be made using codons preferred by the host cell to encode the desired polypeptide. (*See Urdea et al. (1983) Proc. Natl. Acad. Sci. USA 80:7461*). Alternatively, the desired native BBSR polypeptide coding sequences can be cloned from nucleic acid libraries. Techniques for producing and probing nucleic acid sequence libraries are described, for example, in Sambrook et al. (1989)

Molecular Cloning: A Laboratory Manual (New York, Cold Spring Harbor Laboratory). Other recombinant techniques, such as site specific mutagenesis, PCR, enzymatic digestion and ligation, can also be used to construct the desired BBSR protein or polypeptide coding sequence.

- 5 The native BBSR polypeptide coding sequences can be modified to create the other classes of BBSR polypeptides. For example, mutants can be created by making conservative amino acid substitutions that maintain or enhance native BBSR protein or the protein's activity. The following are examples of conservative substitutions: Gly \Leftrightarrow Ala; Val \Leftrightarrow Ile \Leftrightarrow Leu; Asp \Leftrightarrow Glu; Lys \Leftrightarrow Arg; Asn \Leftrightarrow Gln; and
10 Phe \Leftrightarrow Trp \Leftrightarrow Tyr. Mutants can also contain amino acid deletions or insertions compared to the native BBSR polypeptides. Mutants may include substitutions, insertions, and deletions of the native polypeptides.

- Mutants will retain at least about 20% of the one of the activities of the native BBSR protein. The coding sequence of mutants can be constructed by *in vitro*
15 mutagenesis of the native coding sequences.

- Fragments differ from mutant or native BBSR polypeptides by amino and/or carboxyl terminal amino acid deletions. The number of amino acids that are truncated is not critical as long as the BBSR protein fragment retains at least about 20% of the one of the activities of the native BBSR polypeptide. The coding sequence of
20 such fragments can be easily constructed by cleaving the unwanted nucleotides from the mutant or native BBSR polypeptide coding sequences.

- Fusions are fragments, mutants, or native BBSR polypeptides with additional amino acids at either or both of the termini. The additional amino acid sequence is not necessarily homologous to sequence found in native polypeptides. The
25 fusions, just as all BBSR polypeptides, retain at least about 20% of one of the activities of the native BBSR polypeptides. Coding sequence of the fusions can be constructed by ligating synthetic polynucleotides encoding the additional amino acids to fragment, mutant, or native coding sequences. Activities of the BBSR polypeptides can be determined by the methods described *infra*.

At the minimum, an expression vector will contain a promoter which is operable, that is drives expression in the host cell and operably linked to a BBSR protein or polypeptide coding sequence. Sequences that modulate gene expression, such as enhancers and binding sites for inducers or repressors may be present.

5 Expression vectors may also include signal sequences, terminators, selectable markers, origins of replication, and sequences homologous to host cell sequences. These additional elements are optional but can be included to optimize expression. Construction of expression vectors is known in the art and any appropriate methods can be employed with the polynucleotides of the invention.

10 A BBSR protein or polypeptide coding sequence may also be linked in reading frame to a signal sequence. The signal sequence fragment typically encodes a peptide comprised of hydrophobic amino acids which directs the BBSR protein or polypeptide to the cell membrane or other subcellular compartment. Preferably, there are processing sites encoded between the leader fragment and the gene or fragment
15 thereof that can be cleaved either *in vivo* or *in vitro*. DNA encoding suitable signal sequences can be derived from genes for secreted endogenous host cell proteins, such as the yeast invertase gene (EP 12 873; JP 62,096,086), the A-factor gene (U.S. Patent No. 4,588,684), interferon signal sequence (EP 60 057).

After vector construction, the desired BBSR protein and/or BBSR
20 polypeptide expression vector is inserted into the host cell. Many transformation techniques exist for inserting expression vectors into bacterial, yeast, insect, and mammalian cells. The transformation procedure to introduce the expression vector depends upon the host to be transformed. Such methods are known in the art. *See, e.g.*, (Masson et al. (1989) *FEMS Microbiol. Lett.* 60:273; Palva et al. (1982) *Proc. Natl. Acad. Sci. USA* 79:5582; EP Publ. Nos. 036 259 and 063 953; PCT WO 84/04541, *Bacillus*), (Miller et al. (1988) *Proc. Natl. Acad. Sci.* 85:856; Wang et al. (1990) *J. Bacteriol.* 172:949, *Campylobacter*), (Cohen et al. (1973) *Proc. Natl. Acad. Sci.* 69:2110; Dower et al. (1988) *Nuc. Acids Res.* 16:6127; Kushner et al. (1978) "An
25 Improved Method for Transformation of *Escherichia coli* with ColE1-derived plasmids in *Genetic Engineering: Proceedings of the International Symposium on Genetic*
30

- Engineering* (eds. H.W. Boyer and S. Nicosia); Mandel et al. (1970) *J. Mol. Biol.* 53:159; Taketo et al. (1988) *Biochim. Biophys. Acta* 949:318; *Escherichia*, (Chassy et al. (1987) *FEMS Microbiol. Lett.* 44:173, *Lactobacillus*); (Fiedler et al. (1988) *Anal. Biochem.* 170:38, *Pseudomonas*); (Augustin et al. (1990) *FEMS Microbiol. Lett.* 5 66:203, *Staphylococcus*), Barany et al. (1980) *J. Bacteriol.* 144:698; Harlander et al. (1987) "Transformation of *Streptococcus lactis* by electroporation," in *Streptococcal Genetics* (ed. J. Ferretti and R. Curtiss, III); Perry et al. (1981) *Infect. Immun.* 32:1295; Powell et al. (1988) *Appl. Environ. Microbiol.* 54:655; Somkuti et al. (1987) *Proc. 4th Evr. Cong. Biotechnology* 1:412, *Streptococcus*).
- 10 Transformation methods for yeast hosts are well-known in the art, and typically include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Electroporation is another means for transforming yeast hosts. See, for example, *Methods in Enzymology*, Volume 194, 1991, "Guide to Yeast Genetics and Molecular Biology." Transformation procedures usually vary with the yeast species to
- 15 be transformed. See, e.g., (Kurtz et al. (1986) *Mol. Cell. Biol.* 6:142; Kunze et al. (1985) *J. Basic Microbiol.* 25:141, *Candida*); (Gleeson et al. (1986) *J. Gen. Microbiol.* 132:3459; Roggenkamp et al. (1986) *Mol. Gen. Genet.* 202:302, *Hansenula*); (Das et al. (1984) *J. Bacteriol.* 158:1165; De Louvencourt et al. (1983) *J. Bacteriol.* 154:1165; Van den Berg et al. (1990) *Biotechnology* 8:135, *Kluyveromyces*); (Cregg et al. (1985)
- 20 *Mol. Cell. Biol.* 5:3376; Kunze et al. (1985) *J. Basic Microbiol.* 25:141; U.S. Patent Nos. 4,837,148 and 4,929,955, *Pichia*); (Hinnen et al. (1978) *Proc. Natl. Acad. Sci. USA* 75:1929; Ito et al. (1983) *J. Bacteriol.* 153:163, *Saccharomyces*); (Beach and Nurse (1981) *Nature* 300:706, *Schizosaccharomyces*); (Davidow et al. (1985) *Curr. Genet.* 10:39; Gaillardin et al. (1985) *Curr. Genet.* 10:49, *Yarrowia*).
- 25 Methods for introducing heterologous polynucleotides into mammalian cells are known in the art and include viral infection, dextran-mediated transfection, calcium phosphate precipitation, microparticle bombardment, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

Monitoring BBSR Polypeptide Expression Levels

Immunoassays and ligand binding assays can be utilized to confirm that the transformed host cell is expressing the desired BBSR polypeptide. Polyclonal or monoclonal antibodies to BBSR proteins can be prepared by any methods known in the art, using as immunogen the whole BBSR protein or an epitope-bearing portion thereof, which can comprise between about 10 and 100 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:9, preferably between about 12 and 50 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:9, more preferably between about 15 and 25 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:9.

For example, an immunofluorescence assay can be performed on transformed host cells without separating the BBSR polypeptides from the cell. The host cells are first fixed onto a solid support, such as a microscope slide or microtiter well. This fixing step permeabilizes the cell membrane. Next, the fixed host cells are exposed to an anti-BBSR polypeptide antibody. Preferably, to increase the sensitivity of the assay, the fixed cells are exposed to a second antibody, which is labeled and binds to the anti-BBSR polypeptide antibody. Typically, the secondary antibody is labeled with a fluorescent marker. The host cells, which express the BBSR polypeptides, will be fluorescently labeled and easily visualized under the microscope. See, for example, Hashido et al. (1992) *Biochem & Biophys. Res. Comm.* 187(3):1241-1248.

Also, the BBSR polypeptides do not need to be separated from the cell membrane for *in vitro* assays. The host cells may be fixed to a solid support, such as a microtiter plate. Alternatively, a crude membrane fraction can be separated from lysed host cells by centrifugation (See Adachi et al. (1992) *FEBS Lett* 311(2):179-183. The fixed host cells or the crude membrane fraction is exposed to labeled ligand or ion. Typically, the ligand is labeled with radioactive atoms. The host cells, which express the desired BBSR polypeptide, will bind with the labeled ligand, which can be easily detected.

BBSR polypeptides can be purified and are useful as compositions, for assays, and to produce antibodies. BBSR polypeptides can be isolated by a variety of steps including, for example, anion exchange chromatography, size exclusion chromatography, hydroxylapatite chromatography, hydrophobic interaction chromatography, metal chelation chromatography, reverse phase HPLC, affinity
5 chromatography, and further ammonium sulfate precipitations. These techniques are well known to those of skill in the art.

For ligand binding studies, patch clamp analysis or other *in vitro* assays, the crude cell membrane fractions can be utilized. These membrane extracts can be
10 isolated from cells, which expressed BBSR polypeptides by lysing the cells. Alternatively, whole cells, expressing BBSR polypeptides, can be cultured in a microtiter plate.

Antibodies

Antibodies against BBSR polypeptides are useful for affinity
15 chromatography, immunofluorescent assays, and distinguishing BBSR polypeptides; and for inhibiting or modulating an activity or biological effect or a disorder associated with the BBSR-proteins of the invention. Such uses include but are not limited to modulation of BBSR-mediated disorders; modulation of transcription, particularly that of apo A1, modulation of ion transport, cholesterol homeostasis, and the like.

20 Antibodies to the proteins of the invention, both polyclonal and monoclonal, may be prepared by conventional methods known to those skilled in the art. For example, monoclonal antibodies are prepared using the method of Kohler et al. (1975) *Nature* 256:495-496, or a modification thereof.

If desired, the antibodies (whether polyclonal or monoclonal) may be
25 labeled using conventional techniques. Suitable labels include fluorophores, chromophores, radioactive atoms (particularly ^{32}P and ^{125}I), electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes are typically detected by their activity. For example, horseradish peroxidase is usually detected by its ability to convert 3,3',5,5'-tetra-methylbenzidine (TMB) to a blue pigment, quantifiable with a

spectrophotometer. "Specific binding partner" refers to a protein capable of binding a ligand molecule with high specificity, as for example in the case of an antigen and a monoclonal antibody specific therefor. Other specific binding partners include biotin and avidin or streptavidin, IgG and protein A, and the numerous receptor-ligand couples known in the art. It should be understood that the above description is not meant to categorize the various labels into distinct classes, as the same label may serve in several different modes. For example, ^{125}I may serve as a radioactive label or as an electron-dense reagent. HRP may serve as enzyme or as antigen for a MAb. Further, one may combine various labels for desired effect. For example, MAbs and avidin also require labels in the practice of this invention: thus, one might label a MAb with biotin, and detect its presence with avidin labeled with ^{125}I , or with an anti-biotin MAb labeled with HRP. Other permutations and possibilities will be readily apparent to those of ordinary skill in the art, and are considered as equivalents within the scope of the instant invention.

15 Ion Transport Activity

The channel forming and ion transport activity of the plasmolipin-like polypeptide (SEQ ID NO:4) is determined essentially as described in U.S. Patent No. 5,843,714. The plasmolipin-like polypeptide is assayed by monitoring its effect on transmembrane pH gradients in liposomes. Mitochondrial cytochrome C oxidase, a proton pump, is reconstituted into liposomes by sonication. The pH-sensitive fluorescent dye pyranine (Eastman Kodak) is then incorporated into the proteoliposomes by rapid freeze-thawing and sonication. Excess dye is removed by centrifugation and resuspension of the liposomes into an appropriate buffer. Addition of ascorbate and cytochrome C initiates proton uptake into the liposomes. PLP protein is added and proton efflux is monitored by the fluorescence changes arising from changes in internal pH of the liposomes at excitation and emission wavelengths of 460 nm and 508 nm, respectively.

Lipid bilayer destabilization promoted by the plasmolipin-like polypeptide, incorporated into membranes by expression or by reconstitution, is assayed

by measurement of the fluorescence polarization of the lipophilic dye 1,6-diphenyl-1,3,5-hexatriene (Eastman Kodak) inserted into the membranes.

Screening for Agonists and Antagonists

BBSR polypeptides can also be used to screen combinatorial libraries to
5 identify agonist or antagonists. For example, a "library" of peptides may be synthesized following the methods disclosed in U.S. Patent No. 5,010,175, and in PCT WO 91/17823, both incorporated herein by reference in full. The peptide library is first screened for binding to the selected BBSR polypeptide. The peptides are then tested for their ability to inhibit or enhance the particular BBSR protein activity. Peptides
10 exhibiting the desired activity are then isolated and sequenced.

Agonists or antagonists of BBSR proteins may be screened using any available method. The assay conditions ideally should resemble the conditions under which the activity of the particular BBSR protein is exhibited *in vivo*, i.e., under physiologic pH, temperature, ionic strength, etc. Suitable agonists or antagonists will
15 exhibit strong inhibition or enhancement of the particular activity of the BBSR protein at concentrations, which do not raise toxic side effects in the subject. Agonists or antagonists which compete for binding to the BBSR polypeptide may require concentrations equal to or greater than the native BBSR protein concentration, while inhibitors capable of binding irreversibly to the polypeptide may be added in
20 concentrations on the order of the native BBSR protein concentration.

Pharmaceutical Compositions

Pharmaceutical compositions can comprise either polypeptides, antibodies, or polynucleotides of the claimed invention.⁶ The pharmaceutical compositions will comprise a therapeutically effective amount of either polypeptides,
25 antibodies, or polynucleotides of the claimed invention.

The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be

detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics
5 selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation can be determined by routine experimentation and is within the judgment of the clinician.

For purposes of the present invention, an effective dose will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the polypeptide or
10 DNA construct in the individual to which it is administered

A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not
15 itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in
20 the art.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is
25 available in *Remington's Pharmaceutical Sciences* (1991) (Mack Pub. Co., NJ).

Pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Typically, the therapeutic compositions are
30 prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for

solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.

Delivery Methods

Once formulated, the compositions of the invention can be administered
5 directly to the subject. The subjects to be treated can be mammals or birds. In particular, human subjects can be treated.

Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue. The compositions can also be administered
10 into a tumor or lesion. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal applications, needles, and gene guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.

Alternatively, the BBSR polypeptides could be stably expressed in an
15 organ of a mammal, and then the organ could be xenografted into a human in need of such treatment.

Gene Delivery Vehicles

Gene therapy vehicles for delivery of constructs including a coding sequence of a therapeutic of the invention, to be delivered to the mammal for expression
20 in the mammal, can be administered either locally or systemically. These constructs can utilize viral or non-viral vector approaches in *in vivo* or *ex vivo* modality. Expression of such coding sequence can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence *in vivo* can be either constitutive or regulated.

25 The invention includes gene delivery vehicles capable of expressing the contemplated nucleic acid sequences. The gene delivery vehicle is preferably a viral vector and, more preferably, a retroviral, adenoviral, adeno-associated viral (AAV), herpes viral, or alphavirus vector. The viral vector can also be an astrovirus,

coronavirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picornavirus, poxvirus, or togavirus viral vector. *See generally*, Jolly et al. (1994) *Cancer Gene Therapy* 1:51-64; Kimura et al. (1994) *Human Gene Therapy* 5:845-852; Connelly et al. (1995) *Human Gene Therapy* 6:185-193; and Kaplitt et al. (1994) *Nature Genetics* 5 6:148-153.

Retroviral vectors are well known in the art and it is contemplated that any retroviral gene therapy vector is employable in the invention, including B, C and D type retroviruses, xenotropic retroviruses (for example, NZB-X1, NZB-X2 and NZB9-1 (see O'Neill (1985) *J. Vir.* 53:160) polytropic retroviruses (for example, MCF and 10 MCF-MLV (see Kelly et al. (1983) *J. Vir.* 45:291), spumaviruses and lentiviruses. *See RNA Tumor Viruses*, Second Edition, Cold Spring Harbor Laboratory, 1985.

Portions of the retroviral gene therapy vector may be derived from different retroviruses. For example, retrovector LTRs may be derived from a Murine Sarcoma Virus, a tRNA binding site from a Rous Sarcoma Virus, a packaging signal 15 from a Murine Leukemia Virus, and an origin of second strand synthesis from an Avian Leukosis Virus.

These recombinant retroviral vectors may be used to generate transduction competent retroviral vector particles by introducing them into appropriate packaging cell lines (see US Serial No. 07/800,921, filed November 29, 1991). 20 Retrovirus vectors can be constructed for site-specific integration into host cell DNA by incorporation of a chimeric integrase enzyme into the retroviral particle. *See*, US Serial No. 08/445,466 filed May 22, 1995. It is preferable but not required that the recombinant viral vector is a replication defective recombinant virus.

Packaging cell lines suitable for use with the above-described retrovirus 25 vectors are well known in the art, are readily prepared (see US Serial No. 08/240,030, filed May 9, 1994; see also WO 92/05266), and can be used to create producer cell lines (also termed vector cell lines or "VCLs") for the production of recombinant vector particles. Preferably, the packaging cell lines are made from human parent cells (e.g., HT1080 cells) or mink parent cell lines, which eliminates inactivation in human serum.

Preferred retroviruses for the construction of retroviral gene therapy vectors include Avian Leukosis Virus, Bovine Leukemia Virus, Murine Leukemia Virus, Mink-Cell Focus-Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis Virus and Rous Sarcoma Virus. Particularly preferred Murine Leukemia Viruses include 4070A and 1504A (Hartley et al. (1976) *J. Virol.* 19:19-25), Abelson (ATCC No. VR-999), Friend (ATCC No. VR-245), Graffi, Gross (ATCC No. VR-590), Kirsten, Harvey Sarcoma Virus and Rauscher (ATCC No. VR-998) and Moloney Murine Leukemia Virus (ATCC No. VR-190). Such retroviruses may be obtained from depositories or collections such as the American Type Culture Collection ("ATCC") in Rockville, Maryland or isolated from known sources using commonly available techniques.

The gene delivery vehicles of the invention also include adenovirus associated virus (AAV) vectors. Leading and preferred examples of such vectors for use in this invention are the AAV-2 based vectors disclosed in Srivastava, WO 93/09239.

Also contemplated are alpha virus gene therapy vectors that can be employed in this invention. Preferred alpha virus vectors are Sindbis viruses vectors. Togaviruses, Semliki Forest virus (ATCC VR-67; ATCC VR-1247), Middleberg virus (ATCC VR-370), Ross River virus (ATCC VR-373; ATCC VR-1246), Venezuelan equine encephalitis virus (ATCC VR923; ATCC VR-1250; ATCC VR-1249; ATCC VR-532), and those described in U.S. patents 5,091,309, 5,217,879, and WO 92/10578, WO 95/07994, U.S. 5,091,309 and U.S. 5,217,879 are employable. Such alpha viruses may be obtained from depositories or collections such as the ATCC in Rockville, Maryland or isolated from known sources using commonly available techniques. Preferably, alphavirus vectors with reduced cytotoxicity are used (*see* co-owned U.S. Serial No. 08/679640).

EXAMPLES

The example presented below is provided as a further guide to the practitioner of ordinary skill in the art, and is not to be construed as limiting the invention in any way.

5

EXAMPLE 1Polynucleotides that map to regions of the human genome
associated with BBS.

A 2850 bp cDNA (SEQ ID NO:1) from human brain (frontal cortex) that encodes an open reading frame of 762 bp (encompassing bases 214-976) was isolated
10 and is referred to herein as Gene X. The Gene X gene is located on human chromosome 16. Northern analysis showed that the transcript of Gene X is expressed in brain (cerebellum, cerebral cortex, medulla, spinal cord, occipital lobe, frontal lobe, temporal lobe and putamen), heart, skeletal muscle, spleen, testis, and pancreas, with very low expression in thymus, ovary, small intestine, colon, peripheral blood
15 leukocytes, placenta, lung liver and kidney. The transcript corresponds to a minimum of 4 exons.

A 1516 bp cDNA (SEQ ID NO:3) was isolated from human brain that encodes an open reading frame of 545 bp (encompassing bases 210-755 bp nucleotide). This gene is located on human chromosome 16. The nucleotide sequence shares
20 homology with rat plasmolipin. At the amino acid level it has about 89% identity with rat plasmolipin and with NTII-11. The transcript of this novel gene is expressed in brain, kidney, lung, pancreas, spleen, prostate, heart, testis, small intestine, liver, colon, skeletal muscle, placenta and ovary, but is not visible on Northern blots of thymus and peripheral blood leukocytes.

25 A 2177 bp cDNA (SEQ ID NO:5) was isolated from human retina that encodes an open reading frame of 891 bp (encompassing bases 167-1057). This gene is located on human chromosome 15. At the nucleotide level it contains over 70% identity with several transcription factors (e.g., tailless, chick ovalbumin upstream promoter transcription factor II, apolipoprotein AI regulatory protein) over regions

spanning 224 bp. The transcript of this novel gene is about 1.5 kb on Northern and was expressed in brain (cerebellum, cerebral cortex, medulla, spinal cord, occipital lobe, frontal lobe, temporal lobe and putamen), heart, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood leukocytes. The transcript contains an open reading frame of 891 bp encompassing bases 167-1057 and predicts a protein of 297 amino acids.

Two fragments of 214 bp (SEQ ID NO:7) and 65 bp were identified which are located on BAC 17354 (from human chromosome 16). A 126 bp fragment was isolated for use as a probe for hybridization on Northern blots and this probe identified a transcript of ~2.3 kb that was present in brain (cerebellum, cerebral cortex, medulla, spinal cord, occipital lobe, frontal lobe, temporal lobe and putamen), heart, placenta, lung, liver skeletal muscle, kidney, pancreas, spleen, prostate, ovary, small intestine, colon, and peripheral blood leukocytes. A slightly larger transcript, ~2.4 kb, was present in testis and no expression appeared in thymus RNA.

Identities were determined using MPSRCH™ software, Release 3.3A (distributed by Oxford Molecular Ltd.). Nucleotide identity determinations were made using MPSRCH_nn, using Smith-Waterman algorithm using default TABLE Gap 6.

Protein identity determinations were made either using MPsrch-PP, using Smith-Waterman algorithm, using blosum 60 TABLE, Gap 14; or by using blosum 60 TABLE, Base Gap open 24, Gap extend 3, A-A Gap open 30, Gap extend 9.

All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

CLAIMS

1. An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:

- (a) a polynucleotide encoding amino acids from about 1 to about 254 of SEQ ID NO:2;
- (b) a polynucleotide encoding amino acids from about 2 to about 254 of SEQ ID NO:2;
- (c) a polynucleotide encoding amino acids from about 1 to about 218 of SEQ ID NO:4;
- (d) a polynucleotide encoding amino acids from about 2 to about 218 of SEQ ID NO:4;
- (e) a polynucleotide encoding amino acids from about 1 to about 297 of SEQ ID NO:6;
- (f) a polynucleotide encoding amino acids from about 2 to about 297 of SEQ ID NO:6;
- (g) a polynucleotide encoding amino acids from about 1 to about 513 of SEQ ID NO:9;
- (h) a polynucleotide encoding amino acids from about 2 to about 513 of SEQ ID NO:9;
- (i) a polynucleotide consisting of SEQ ID NO:7;
- (j) the polynucleotide complement of the polynucleotide of any one of (a) through (i); and
- (k) a polynucleotide at least 90% identical to the polynucleotide of any one of (a) through (j).

2. An isolated nucleic acid molecule comprising about 762 contiguous nucleotides from the coding region of SEQ ID NO:1, about 545 contiguous nucleotides from the

coding region of SEQ ID NO:3, about 891 contiguous nucleotides from the coding region of SEQ ID NO:5, or about 1539 contiguous nucleotides from the coding region of SEQ ID NO:8.

3. An isolated nucleic acid molecule comprising a polynucleotide encoding a polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has an amino acid sequence selected from the group consisting of:

- (a) amino acids from about 1 to about 254 of SEQ ID NO:2;
- (b) amino acids from about 2 to about 254 of SEQ ID NO:2;
- (c) amino acids from about 1 to about 218 of SEQ ID NO:4;
- (d) amino acids from about 2 to about 218 of SEQ ID NO:4;
- (e) amino acids from about 1 to about 297 of SEQ ID NO:6;
- (f) amino acids from about 2 to about 297 of SEQ ID NO:6;
- (g) amino acids from about 1 to about 513 of SEQ ID NO:9;
- (h) amino acids from about 2 to about 513 of SEQ ID NO:9.

4. The isolated nucleic acid molecule of claim 1, which is DNA.

5. A method of making a recombinant vector comprising inserting a nucleic acid molecule of claim 1 into a vector in operable linkage to a promoter.

6. A recombinant vector produced by the method of claim 5.

7. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 6 into a host cell.

8. A recombinant host cell produced by the method of claim 7.

9. A recombinant method of producing a polypeptide, comprising culturing the recombinant host cell of claim 8 under conditions such that said polypeptide is expressed and recovering said polypeptide.

10. An isolated polypeptide comprising amino acids at least 95% identical to amino acids selected from the group consisting of:

- (a) amino acids from about 1 to about 254 of SEQ ID NO:2;
- (b) amino acids from about 2 to about 254 of SEQ ID NO:2;
- (c) amino acids from about 1 to about 218 of SEQ ID NO:4;
- (d) amino acids from about 2 to about 218 of SEQ ID NO:4;
- (e) amino acids from about 1 to about 297 of SEQ ID NO:6;
- (f) amino acids from about 2 to about 297 of SEQ ID NO:6;
- (g) amino acids from about 1 to about 513 of SEQ ID NO:9;
- (h) amino acids from about 2 to about 513 of SEQ ID NO:9.

11. An isolated polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has an amino acid sequence selected from the group consisting of:

- (a) amino acids from about 1 to about 254 of SEQ ID NO:2;
- (b) amino acids from about 2 to about 254 of SEQ ID NO:2;
- (c) amino acids from about 1 to about 218 of SEQ ID NO:4;
- (d) amino acids from about 2 to about 218 of SEQ ID NO:4;
- (e) amino acids from about 1 to about 297 of SEQ ID NO:6;
- (f) amino acids from about 2 to about 297 of SEQ ID NO:6;
- (g) amino acids from about 1 to about 513 of SEQ ID NO:9;
- (h) amino acids from about 2 to about 513 of SEQ ID NO:9.

12. An isolated polypeptide comprising amino selected from the group consisting of:
- (a) amino acids from about 1 to about 254 of SEQ ID NO:2;
 - (b) amino acids from about 2 to about 254 of SEQ ID NO:2;
 - (c) amino acids from about 1 to about 218 of SEQ ID NO:4;
 - (d) amino acids from about 2 to about 218 of SEQ ID NO:4;
 - (e) amino acids from about 1 to about 297 of SEQ ID NO:6;
 - (f) amino acids from about 2 to about 297 of SEQ ID NO:6;
 - (g) amino acids from about 1 to about 513 of SEQ ID NO:9;
 - (h) amino acids from about 2 to about 513 of SEQ ID NO:9.
-
13. An epitope-bearing portion of a polypeptide selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:9.
14. The epitope-bearing portion of claim 13, which comprises between about 10 and 100 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:9.
15. The epitope-bearing portion of claim 14, which comprises between about 12 and 50 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:9.
16. The epitope-bearing portion of claim 14, which comprises between about 15 and 25 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:9.
17. An isolated antibody that binds specifically to the polypeptide of claim 10.

18. An isolated antibody that binds specifically to the polypeptide of claim 11.
19. An isolated antibody that binds specifically to the polypeptide of claim 12.
20. A method for diagnosing a BBSR protein-modulated disorder using a biological sample from a human suspected of having said disorder, said method comprising :
 - a) providing an antibody that binds to the polypeptide of claim 10;
 - b) contacting the antibody with said sample under binding conditions to form a duplex; and
 - c) determining the amount of said duplex formed, compared to a normal sample.
21. A method for diagnosing a BBSR protein-modulated disorder in a biological sample from a human suspected of having said disorder, said method comprising:
 - a) providing a polynucleotide that binds to mRNA encoding the polypeptide of claim 10 under stringent conditions;
 - b) contacting nucleic acid of said sample with said polynucleotide under binding conditions to form a duplex; and
 - c) determining the amount of said duplex formed, compared to a normal sample.
22. A method for modulating the amount of a BBSR protein in a subject, said method comprising administering an effective amount of a composition selected from a group consisting of:
 - a) the polypeptide according to claim 10; and
 - b) an antibody that binds to the polypeptide according to claim 10.

23. A method for modulating the amount of a BBSR protein in a subject, said method comprising administering an effective amount of a composition consisting of the nucleotide sequence according to claim 1.

24. A method for treating a BBSR protein-modulated disorder in a subject, said method comprising administering to said subject an effective amount of a composition selected from a group consisting of:

- a) the polypeptide according to claim 10; and
- b) an antibody that binds to the polypeptide according to claim 10; wherein said composition further comprises a pharmaceutically acceptable carrier.

25. A method for treating a BBSR protein-modulated disorder in a subject, said method comprising administering to said subject an effective amount of a composition consisting of the nucleotide sequence according to claim 1, wherein said composition further comprises a pharmaceutically acceptable carrier.

1/14

Nucleotide and Amino Acid
Sequences of Gene X

```

aagccctgaa ggggtcaaaag aaatacaaaa gcaaaggcta ttttcttttt ttttttcttt 60
ctttcattcm ttccttcctc tgtttctttc tttcttcctt tcattttttt ttctttttta 120
agagcgagcg gctctgcggt ggcggttttg ggtgggcgcc gccgaggtga ggtcgtctcg 180
cctcccgcg cccggtagat tggttgtttc att atg gat gga ggg gat gat ggt 234
                               Met Asp Gly Gly Asp Asp Gly
                               1           5

aac ctt att atc aaa aag agg ttt gtg tct gag gca gaa cta gat gaa 282
Asn Leu Ile Ile Lys Lys Arg Phe Val Ser Glu Ala Glu Leu Asp Glu
          10           15           20

cgg cgc aaa agg agg caa gaa gaa tgg gag aaa gtt cga aaa cct gaa 330
Arg Arg Lys Arg Arg Gln Glu Glu Trp Glu Lys Val Arg Lys Pro Glu
          25           30           35

gat cca gaa gaa tgt cca gag gag gtt tat gac cct cga tct cta tat 378
Asp Pro Glu Glu Cys Pro Glu Glu Val Tyr Asp Pro Arg Ser Leu Tyr
40           45           50           55

gaa agg cta cag gaa cag aag gac agg aag cag cag gag tac gag gaa 426
Glu Arg Leu Gln Glu Gln Lys Asp Arg Lys Gln Gln Glu Tyr Glu Glu
          60           65           70

cag ttc aaa ttc aaa aac atg gta aga ggc tta gat gaa gat gag acc 474
Gln Phe Lys Phe Lys Asn Met Val Arg Gly Leu Asp Glu Asp Glu Thr
          75           80           85

aac ttc ctt gat gag gtt tct cga cag cag gaa cta ata gaa aag caa 522
Asn Phe Leu Asp Glu Val Ser Arg Gln Gln Glu Leu Ile Glu Lys Gln
          90           95           100

cga aga gaa gaa gaa ctg aaa gaa ctg aag gaa tac aga aat aac ctc 570
Arg Arg Glu Glu Glu Leu Lys Glu Leu Lys Glu Tyr Arg Asn Asn Leu
105           110           115

```

Fig. 1A

SUBSTITUTE SHEET (RULE 26)

2/14

aag aag gtt gga att tct caa gag aac aag aag gaa gtg gaa aag aaa 618
 Lys Lys Val Gly Ile Ser Gln Glu Asn Lys Lys Glu Val Glu Lys Lys
 120 125 130 135

ctg act gtg aag cct ata gaa acc aag aac aag ttc tcc cag gcg aag 666
 Leu Thr Val Lys Pro Ile Glu Thr Lys Asn Lys Phe Ser Gln Ala Lys
 140 145 150

ctg ttg gca gga gct gtg aag cat aag agc tca gag agt ggc aac agt 714
 Leu Leu Ala Gly Ala Val Lys His Lys Ser Ser Glu Ser Gly Asn Ser
 155 160 165

gtg aaa aga ctg aaa ccg gac cct gag cca gat gac aag aat caa gag 762
 Val Lys Arg Leu Lys Pro Asp Pro Glu Pro Asp Asp Lys Asn Gln Glu
 170 175 180

ccc tca tcc tgc aag tct ctc gga aac acc tcc ctg agt ggc ccc tcc 810
 Pro Ser Ser Cys Lys Ser Leu Gly Asn Thr Ser Leu Ser Gly Pro Ser
 185 190 195

atc cac tgc ccc tct gct gca gta tgt atc ggc atc ctc cca ggc ctg 858
 Ile His Cys Pro Ser Ala Ala Val Cys Ile Gly Ile Leu Pro Gly Leu
 200 205 210 215

ggt gcc tac tct ggg agc agc gac tcc gag tcc agc tca gac agc gaa 906
 Gly Ala Tyr Ser Gly Ser Ser Asp Ser Glu Ser Ser Ser Asp Ser Glu
 220 225 230

ggc acc atc aat gcc acc gga aag att gtc tcc tcc atc ttc cga acc 954
 Gly Thr Ile Asn Ala Thr Gly Lys Ile Val Ser Ser Ile Phe Arg Thr
 235 240 245

aac acc ttc ctc gag gcc ccc tagtttctcc gtccctacac agggagctcc 1005
 Asn Thr Phe Leu Glu Ala Pro
 250

tccccaaggg tagatcggac cgttcattgct gcctataggc attatgtccc tcaaaaaaaaa 1065

actcctttgc ctgcatcctg tgtacaacat gacatttttta accaatccaa tctaaaaatg 1125

tgccagaatc cacctgtggc ccgaatcgtg tttggttcct ctttctactc cactgcagat 1185

Fig. 1B

SUBSTITUTE SHEET (RULE 26)

3/14

gaccaaacct gtcccgtgc cactttctc actgatattg ggaggagggc aaggcccagc 1245
cgaagtcca ctaaaaatgc cccaggagaa taggcaccgg ctggcttgcc aaagggtttg 1305
ggttttattg ctttctgttt tttcttttcc cgacagcaca aagaagtaag ggcagttatt 1365
ggacaggtgt tatttaaaca ttctattgta aatgaatgtg ttgtttggtt ctactgcatt 1425
gtggagcatg cgggggaaga gaactgaccc aggtaatgaa atggagccct tccctggaac 1485
taaccagtcc ttgatgttgt gtgactaagt aaagatgata aaccccatct gctgggggtg 1545
tcacttcaca ctcgcatgc atttgaaaag ctttcacatac ccttggccat tccctctctc 1605
ctctctctcc aaccccatct atgcaggaag ggactgctaa caagaacgct tccatctcaa 1665
accttttctc tgcctgggaa attattttat gtttgttttt gaaataaagg atttagttta 1725
agattctaaa ttttagagaa acaaacgtag gccttgttta ctaatagcca gacatcagaa 1785
ctgcaggtag gtatgttaat gagatgactt atttctggca gctcctggaa tcctaatt 1845
gtaaatgagt gggacacact tgcattattgt gaccattcta ttgaggccct ctctgtttta 1905
tgcattattat acttgctgtt ttaactgtgg aatctatttc taacctaaag gtgctgcctt 1965
agtacttttc ttgctgcct ctgctgctct ttttcctttc caaacagcaa ctctgaggcc 2025
atgagcagcc aaaaactaga ggtactgctc cacctcgtct cataaaggga aacgggctca 2085
tcccttggtat tctggaggag ggagagggag atggtgtgga ggcctcgagg acagagatag 2145
acatgagctt tgacaacaat ctgtaggctc tcctgcttta gaataagcat gtaccattct 2205
ttatccattc cccttattcc tacatcaatt gtttttactt tcttgggtgt gagactgagt 2265
gagacacaca caaatgtgt tgacactgtg atgccggcag gcagagcagc tactgacttt 2325
gaacatgggc agagaggccc ctggatctca tccagcccac tccttttccc cttccagtac 2385
agtgacactc tggtgcccat tggcagatgg cgacttcctt gcaccataa ctgatgcttt 2445

Fig. 1C

SUBSTITUTE SHEET (RULE 26)

4/14

gtgaattctt cctccttttc agaactactc tgtgctaatt gttctgccag tatgggcgca 2505
tcagctccat cctgacaaac aagacattta ggtaaaactt tgtaggcacc ttctgcttct 2565
ctgcttcatt gttcctgtga tagtcctggt gttattacag catgtacca aaacagcctc 2625
acattgttac aggaggcagg ccaggacatc aaagtcatca tctttatgtg gcatgactct 2685
taagaggcca ttactgtatc tcatggcctc ttgatgtgga aagaagttga cagaggggtg 2745
cagggtttaaa aaacatccat taacatgaaa gctaataaac ctgtcagaga aaaaaaaaaa 2805
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 2850

Fig. 1D

SUBSTITUTE SHEET (RULE 26)

5/14

Nucleotide and Amino Acid Sequences of
Plasmolipin Like Protein (PLP)

```

cgtccggagc ctgggggaaa agcggcgcgg gagccggcac ccaccgctgg aggggcggcg 60
acggcgggccg tagcgacctc gggaggcaag cggagccgcc atg gcc gag ttc ccg 115
                                     Met Ala Glu Phe Pro
                                     1           5

tcg aaa gtt agc acg cgg acc agc agt cct gcg cag ggc gcc gaa gcc 163
Ser Lys Val Ser Thr Arg Thr Ser Ser Pro Ala Gln Gly Ala Glu Ala
                10                15                20

tcg gtg tcg gcg ctg cgc ccg gac ctg ggc ttc gtg cgc tcc cgc ctc 211
Ser Val Ser Ala Leu Arg Pro Asp Leu Gly Phe Val Arg Ser Arg Leu
                25                30                35

ggg gcg ctc atg ctg ctg cag ctg gtg ctg ggg ctg ctg gtg tgg gcg 259
Gly Ala Leu Met Leu Leu Gln Leu Val Leu Gly Leu Leu Val Trp Ala
                40                45                50

ctg att gcg gac acc ccg tac cac ctg tat ccg gcc tat ggc tgg gtg 307
Leu Ile Ala Asp Thr Pro Tyr His Leu Tyr Pro Ala Tyr Gly Trp Val
                55                60                65

atg ttc gtc gct gtc ttc ctc tgg ctg gtg aca atc gtc ctc ttc aac 355
Met Phe Val Ala Val Phe Leu Trp Leu Val Thr Ile Val Leu Phe Asn
                70                75                80                85

ctc tac ctg ttt cag ctg cac atg aag ttg tac atg gtt ccc tgg cca 403
Leu Tyr Leu Phe Gln Leu His Met Lys Leu Tyr Met Val Pro Trp Pro
                90                95                100

ctg gtg tta atg atc ttt aac atc agc gcc acc gtt ctc tac atc acc 451
Leu Val Leu Met Ile Phe Asn Ile Ser Ala Thr Val Leu Tyr Ile Thr
                105                110                115

gcc ttc atc gcc tgc tct gcg gca gtt gac ctg aca tcc ctg agg ggc 499
Ala Phe Ile Ala Cys Ser Ala Ala Val Asp Leu Thr Ser Leu Arg Gly
                120                125                130

```

Fig. 2A

SUBSTITUTE SHEET (RULE 26)

6/14

acc cgg cct tat aac cag cgc gcg gct gcc tcg ttc ttt gcg tgt ttg 547
 Thr Arg Pro Tyr Asn Gln Arg Ala Ala Ala Ser Phe Phe Ala Cys Leu
 135 140 145

gtg atg atc gcc tat gga gtg agt gcc ttc ttc agc tac cag gcc tgg 595
 Val Met Ile Ala Tyr Gly Val Ser Ala Phe Phe Ser Tyr Gln Ala Trp
 150 155 160 165

cga gga gta ggc agc aat gcg gcc acc agt cag atg gct ggc ggc tat 643
 Arg Gly Val Gly Ser Asn Ala Ala Thr Ser Gln Met Ala Gly Gly Tyr
 170 175 180

gcc taa acc acc tgt gcc acg gcc ccc tct ggg gct gaa gcc gcc gct 691
 Ala Thr Thr Cys Ala Thr Ala Pro Ser Gly Ala Glu Ala Ala Ala
 185 190 195

ggg tca cag agc agg gtc acc ctg caa gcc tga agc tgg gga gcc ctg 739
 Gly Ser Gln Ser Arg Val Thr Leu Gln Ala Ser Trp Gly Ala Leu
 200 205 210

cgt gga gtc agc cca acagggactg catttgctcc tctctgcccgc tcagacataa 794
 Arg Gly Val Ser Pro
 215

gctctcacag cgctaaggaa gcaggcccag gctggcaggc atctcggctt gcaggaggcc 854
 aactgctgag acctcttctc catccccctt attcagtgga agatgacggg ggatctgagg 914
 ctgtgtctct gccttgcttt tagaggactt cagcgtccaa gactggggcc cacccttctc 974
 accagcacta aatgcactaa caaggactcc agacctgcag cccagagccc gccgtagtat 1034
 aagcctaaca agcaacacgt agcaccttag tctttgttcc aggagagctg agcaagctgg 1094
 tgaaaccact ctcttcctt taaacaccgt ttcaaccaac ctctccctgg agccaacctg 1154
 taaaaagtgg gttgattgct gacagcatgg tcttcctcc ctgcatttca gacataccag 1214
 ttactgaaag caaatcagtt ttaagtgatt tctcagtct gaaaagcctg tccaggtttc 1274
 ctccctttc ccaagcctct ctctgtaata ctccctttgg gcgaagctaa catcggtgcc 1334

Fig. 2B

SUBSTITUTE SHEET (RULE 26)

7/14

tccccgacct tgctgactag gcacatggga cgcaaaggag ggaggggaagc aaggccttgc 1394
ctggcgagtt gtcattgtgt tggtggtgac tgttttatatt tttttaataa aaataaagat 1454
gagagaaatt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1514
aa 1516

Fig. 2C

SUBSTITUTE SHEET (RULE 26)

8/14

Nucleotide and Amino Acid Sequences
of ORPH-PPAR (PPAR)

```

gtgctgtgag gggcttcggg accttggggc agctcctgag ttcagacaga gttcaggaag 60
ggagacaggg gcacagagag acagaggttc atggactgag gcaaaggctg ggccaggctc 120
agcaaccag gcctcccgca ggcaggcaga ggctgccctg taaccc atg gag acc 175
                                     Met Glu Thr
                                     1

aga cca aca gct ctg atg agc tcc aca gtg gct gca gct gcg cct gca 223
Arg Pro Thr Ala Leu Met Ser Ser Thr Val Ala Ala Ala Pro Ala
      5              10              15

gct ggg gct gcc tcc agg aag gag tct cca ggc aga tgg ggc ctg ggg 271
Ala Gly Ala Ala Ser Arg Lys Glu Ser Pro Gly Arg Trp Gly Leu Gly
20              25              30              35

gag gat ccc aca ggc gtg agc ccc tcg ctc cag tgc cgc gtg tgc gga 319
Glu Asp Pro Thr Gly Val Ser Pro Ser Leu Gln Cys Arg Val Cys Gly
              40              45              50

gac agc agc agc ggg aag cac tat ggc atc tat gcc tgc aac ggc tgc 367
Asp Ser Ser Ser Gly Lys His Tyr Gly Ile Tyr Ala Cys Asn Gly Cys
              55              60              65

agc ggc ttc ttc aag agg agc gta cgg cgg agg ctc atc tac agg tgc 415
Ser Gly Phe Phe Lys Arg Ser Val Arg Arg Arg Leu Ile Tyr Arg Cys
              70              75              80

cag gtg ggg gca ggg atg tgc ccc gtg gac aag gcc cac cgc aac cag 463
Gln Val Gly Ala Gly Met Cys Pro Val Asp Lys Ala His Arg Asn Gln
      85              90              95

tgc cag gcc tgc cgg ctg aag aag tgc ctg cag gcg ggg atg aac cag 511
Cys Gln Ala Cys Arg Leu Lys Lys Cys Leu Gln Ala Gly Met Asn Gln
100              105              110              115

gac gcc gtg cag aac gag cgc cag ccg cga agc aca gcc cag gtc cac 559
Asp Ala Val Gln Asn Glu Arg Gln Pro Arg Ser Thr Ala Gln Val His
              120              125              130

```

Fig. 3A

SUBSTITUTE SHEET (RULE 26)

9/14

ctg gac agc atg gag tcc aac act gag tcc cgg ccg gag tcc ctg gtg	607
Leu Asp Ser Met Glu Ser Asn Thr Glu Ser Arg Pro Glu Ser Leu Val	
135 140 145	
gct ccc ccg gcc ccg gca ggg cgc agc cca cgg ggc ccc aca ccc atg	655
Ala Pro Pro Ala Pro Ala Gly Arg Ser Pro Arg Gly Pro Thr Pro Met	
150 155 160	
tct gca gcc aga gcc ctg ggc cac cac ttc atg gcc agc ctt ata aca	703
Ser Ala Ala Arg Ala Leu Gly His His Phe Met Ala Ser Leu Ile Thr	
165 170 175	
gct gaa acc tgt gct aag ctg gag cca gag gat gct gat gag aat att	751
Ala Glu Thr Cys Ala Lys Leu Glu Pro Glu Asp Ala Asp Glu Asn Ile	
180 185 190 195	
gat gtc acc agc aat gac cct gag ttc ccc tcc tct cca tac tcc tct	799
Asp Val Thr Ser Asn Asp Pro Glu Phe Pro Ser Ser Pro Tyr Ser Ser	
200 205 210	
tcc tcc ccc tgc ggc ctg gac agc atc cat gag acc tcg gct cgc cta	847
Ser Ser Pro Cys Gly Leu Asp Ser Ile His Glu Thr Ser Ala Arg Leu	
215 220 225	
ctc ttc atg gcc gtc aag tgg gcc aag aac ctg cct gtg ttc tcc agc	895
Leu Phe Met Ala Val Lys Trp Ala Lys Asn Leu Pro Val Phe Ser Ser	
230 235 240	
ctg ccc ttc cgg gat cag gta cct acc ggc ctg cct gct ggg gag cta	943
Leu Pro Phe Arg Asp Gln Val Pro Thr Gly Leu Pro Ala Gly Glu Leu	
245 250 255	
ggc tgg gct ggg gtc agg cgg ccc act cga gtc aac cag aca ggg cac	991
Gly Trp Ala Gly Val Arg Arg Pro Thr Arg Val Asn Gln Thr Gly His	
260 265 270 275	
aca cat ccc cac gcc agt atg aat gca cac agc ttg gat ggt gat ggc	1039
Thr His Pro His Ala Ser Met Asn Ala His Ser Leu Asp Gly Asp Gly	
280 285 290	
tgg gga cac aca tac ctc tgattcagcg atggctgggg tgcattctcag	1087
Trp Gly His Thr Tyr Leu	
295	

Fig. 3B

SUBSTITUTE SHEET (RULE 26)

10/14

ggatggtgac ggtgggggtg catgcatctc tggcacaggg atgatggtcg gggcgcacac 1147
 ctaggagatg atgatggcta gggacctaca gggcccaggg tcttcttaag ttctggaaga 1207
 ccctcaggcc ctgcagacat tctgtgggta acaagtgacc tgcacaccct gaacaggctg 1267
 agtggctgac tctaggcccc cttggagcac aagtgcctac gacttcaggg cttgcatttt 1327
 agttcaatct ctccagctct gggccatccc tctcggcttc taatgggcaa gcagatcttt 1387
 caggaaaacc aggaggagag gcatgaggag ggtttgaggc cctcagccag tctgtgtgct 1447
 ggggtggagc aactcagaag agtcaggcca caccacttga atacactcaa cttaggacac 1507
 tcatgaggca tgtctctgag gctgccaac ttccaatggc tctgggcgtt cctaaatgtc 1567
 ccagctgcag ctctggatgg aaccagtggt ctcagatgat aggcagctga gccggatggt 1627
 gccaaatccc agagctctga gcctctggct gatgtcagga gagcattctc gggctcccagg 1687
 acagcacttc cattccttgg gtgcctgaga tgggtggcaga ggctccagac tgagccagag 1747
 aagctgtgtg tctgccataa caggcacccc tgtctgagca caggatgatcc tgctggaaga 1807
 ggcgtggagt gaactctttc tcctcggggc catccagtgg tctctgcctc tggacagctg 1867
 tcctctgctg gcaccgcccg aggcctctgc tgccgggtgt gccagggcc ggctcacgct 1927
 gccagcatg gagacgcgtg tcctgcagga aactatctct cggttccggg cattggcggt 1987
 ggaccccacg gaggttgcct gcatgaaggc cttggtctc ttcaagccag agacgcgggg 2047
 cctgaaggat cctgagcacg tagaggcctt gcaggaccag tccaagtga tgctgagcca 2107
 gcacagcatt ctagaattaa gcggccgctg aattctaggt taagatggcc cttgacattg 2167
 agcaggtctt 2177

Fig. 3C

SUBSTITUTE SHEET (RULE 26)

11/14

NT2 Like Protein (NTPL) Gene
Fragment Sequence

ACTGNCAGGAACCTCTGCCACCGCCACCGGCTCCCATGGCCACATACCCAGTGGGGGTGCCCCAGCAGCGGGGGCAGCC
CCCATGGGCCCCCAGTATTGCGTGTGCAAGGTGGAGCTGTCAGTGAGTGGCCAGAACCTACTGGACCGGGATGTTACCTC
CAAGTCCGACCCCTTCTGTGTCCTTTACAGAGAACAAATGGCAGATGGATCGAG

Fig. 4

SUBSTITUTE SHEET (RULE 26)

12/14

Seven-transmembrane protein

DNA

GAATTCCCAACAAGGAGTCCAGGGTCTCGCTCTGCTCACACAGGCTGGAGTGC
AGTGGTGATCTTGGCTCATCGGTAACTCCACCTCCCGGGTTCAAGTGATTCTC
TCATGCCCTCAGCCTCCCGAGTAGCTGGGATTACAGGTGGTGACTTCCAAGAG
TGACTCCGTCCGAGGAAATGACTCCCTGCTCCAGCCAGCGGAAACACACAGG
TCCTGCTGAGTCTGCTCTTCCAGCAACCAAGACCTGCGCATCTCAGAACT
AGCAGCCTCCACTACAAAGTCCATGCCCTTCCCTGCGAGCCACCTGCTTCC
CCGAAGAGGCCCTCACAGTCCAGGCCCTTACCACTTCTGCTTCTACTGGAACCG
CGATCCTTCCCTGACCCAGGGGCTCTACCACTTCCCTGCGAGCTTCTTGTGAGTG
ACATGCTGGGAGATTACATCTTCTCTATGGCAAGCGTGACTTCTTGTGCTCA
ACAAAGCCTCTAGCCTCCTTGCTTCCAGCACCAAGGAGGAGCCTGGCTCA
GGCCCCCGCTGTAGCCACTTCTGTCACTCTGCTGGTGAGGCCCTCAGAACCA
TCAGCCTGCCCCAGTGCCGCCAGCTTCACTTCTCTTCCACAGTCTCTCCCCAC
ACGGCCGCTCACAATGCCCTCGGTGGACATGTGCGAGCTCAAAAGGAGCTCTC
AGCTGCTCAGCCAGTTCCTGAAGCATCCCCAGAGGCCCTCAAGGAGGCCCTC
GGCTGCCCCCGCAGCCAGCAGTTGCAAGCCTGGAGTCCGAACTGACCTCT
GTGAGATTCAATGGGGACATGGTGTCTTCCAGGAGGACCGGATCAACGCCA
CGGTGTGGAGCTCCAGGCCACAGCGAGATCATGGAGTACTCGGTGCTGCCTC
CCGGCAGGAGGAGGAGCAGAGCAGGATCCAGGCCCTGCGGTGCTGAGAGT
CGAACACTCTTCCAGAGGACGAAAGGCCGAGGAGGCTGAGAGAGTCCCA
CTCCTCCTGGTGACTTCAGCAGCCAGCTTGGGATTTGTGGTACAGAACCAAGT
GCCACGTCCTGGGTGAGAACGTTGCTTCCAGCAACAGCTACAGCCG
AGCCAACCTCACGGAGCCCGTGGTGTCTTGGGTTTGAAGACCCACATTGAGCA
AAGAAATGTGACTCTGGCAATGTGTCTTGGGTTGAGACCTTTCAGGAGAACCC
GCCCCGGGCATTGGAGCAGTGTGACCTTTCAGTGTGCTGATGGTCTCC
AAACATCCTGCTTCTGCAACCACTTTCAGTGTGCTGCTCCTACG
TCGGTGGAGGTGGACGCCGTGCACAAAGCACTACCTGAGCCTCCTACG

Fig. 5A

Fig. 5B

14/14

TGCTGTTT TGGGGA GTGGTT TCCAGG AGCTGCC CTGGTG TCTGCT GTATA ATG
 TTTGTC TACTG CACAGC CTAGCC CTGAGC CAGGCT CGGTAC CGATG
 CGTGGG CTAGG CTCCCT CAGC ACACG CCACTG GGGCC TTTG TATG AGCTGC ATT
 GCCCTTG CTACCT GACCA AGCA CTGAGC CCACTG CAGT CCGG TCTG GTTTC
 CTGA AGCCCT CTG TGGCA AGA ACTG TGGAC CCACTG GGTG ACAC TGGCCTA
 CATCCCA CCACTC CAAGG ACTGAG ACTGAC CTCTC TCCAG CCCC CAATAG CTCCAGG
 GAGCCTG ACAC TCTC TAAGAG GTTCT CCAAG CCCC CAACAC ACAC CGGTA
 CGCCCTC GGCCTG TTAGG TTAATT CTGT CCAACAC ACAC CGGTA
 GATTGCT GGCCTG TTAGG TTAGG TTAGG TTAGG TTAGG TTAGG TTAGG TTAGG
 CCTCCTG CCAACAT TCA GTCTG GTAGG TTAGG TTAGG TTAGG TTAGG TTAGG
 CTGGAG CTACAG GACAGG GAGC CATTCT TGAAG TTAGG TTAGG TTAGG TTAGG
 CTTCCCTG CAGG AGTCAG CGTTCA ATTCT TTTG TTTG TTTG TTTG TTTG TTTG
 TTTTAC GTACCA ATTCT TTTG TTTG TTTG TTTG TTTG TTTG TTTG TTTG
 TGTAGAGA ATTGG AACTGTAG AAGAG AATCA AGAAG AATAA AATCA
 AGCTGT TGTAA TCGCCT ARCA AAAAA AAAAA AAAAA AAAAA AAAAA
 AAATAA AAAAA AAAAA

Protein

MCE LKRD LQLLSQ FLKHP QKASRR RPSSAAP ASQQ LQSL ES KLTS VRFMG DMVSFE
 EDR INATV WKLQPTAG LQDLHI HSRQ EEEQ SEI MEYS VLLP RTLFQ RTKGRRGEA
 EKRL LLVD FSSQAL FQDK NSSSH VLG EKVLG IVVQNTKV ANLT EPPVLT FQHQLQ
 PKNV TLLQCV FVEDPT LSSP GHWS SALACL VTIAAY LCSR RKPRDYTIKVH MNLLLA
 VEVD AVHKHYLS LSYVGC VVSEAG CRASAI FLHFS LLTCL SWMGL EGYNLYRLVVEV
 VFLL DTSFL LSEPV ALTG SEAGFP IFLV TLVAL VDV DNYGPI ILLAVH RTPEGV IYPSMC
 FGTY VPGY LLKLSAM GWGFLF LFNMA MLATMV VVQILRL RPHTQK WSHVLTLLGLSL
 WIRDSL VSYITNL GLFSLV FLFNMA MLATMV VVQILRL RPHTQK WSHVLTLLGLSL
 VLGLP WALIFFS FASGTFQL VLVLYLFS IITTSFQ GFLIFIWYS MRLQARGGPSPLKS
 NSDSARLP ISSGSTSSRI

Fig. 5C

SUBSTITUTE SHEET (RULE 26)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number
WO 01/00825 A3

(51) International Patent Classification⁷: C12N 15/12,
C07K 14/47, 16/18, A61K 38/17, 39/395

(21) International Application Number: PCT/US00/17375

(22) International Filing Date: 22 June 2000 (22.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/141,753 30 June 1999 (30.06.1999) US

(71) Applicant: CHIRON CORPORATION [US/US]; 4560
Horton Street, Emeryville, CA 94608 (US).

(72) Inventors: DUHL, David; 2720 Camino Lenada, Oak-
land, CA 94611 (US). GORMAN, Susan, Wilkie; #5,
1139 Yale Street, Santa Monica, CA 90403 (US).

(74) Agent: MORLEY, Kimberlin, L.; Chiron Corporation,
Intellectual Property - R338, P.O. Box 8097, Emeryville,
CA 94662-8097 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

(88) Date of publication of the international search report:
5 July 2001

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 01/00825 A3

(54) Title: HUMAN CHROMOSOME 15 AND 16 BARDET-BIEDL SYNDROME POLYNUCLEOTIDES AND POLYPEP-
TIDES AND METHODS OF USE

(57) Abstract: Amino acid and nucleic acid sequences of Bardet-Biedl Syndrome Region (BBSR) that map to human chromosome 15 or 16 are disclosed. Compositions and methods related to the genes and proteins are useful in the study, diagnosis and treatment of a variety of diseases including BBS and related conditions including obesity, retinal degeneration, and disorders affecting the nervous system, the heart, the kidneys, and the like. Compositions include those comprising BBSR polypeptides and derivatives thereof, nucleotide sequences, expression cassettes, vectors, transformed cells and antibodies. Methods include those for expression and detection of BBSR nucleotides and polypeptides.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/17375

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C07K16/18 A61K38/17 A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 679 716 A (MATSUBARA KENICHI ;OKUBO KOUZAKU (JP)) 2 November 1995 (1995-11-02) abstract compare nt 1018-1133 of seq. ID 1 of the present application with nt 1-116 of seq. 3042 in EP0679716 ---	1,3-19
P,X	WO 99 47669 A (SCHMITT ARMIN ;SPECHT THOMAS (DE); DAHL EDGAR (DE); HINZMANN BERND) 23 September 1999 (1999-09-23) abstract compare aa 1-151 of seq. 2 of the present application with aa 13-163 of seq.141 in W09947669. --- -/--	1-19



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 December 2000

Date of mailing of the international search report

18.12.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Galli, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/17375

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL SEQUENCES [Online] Accession No. AF137386, 1 June 1999 (1999-06-01) XIE B.: "Molecular cloning of human plasmolipin cDNA." XP002154793 compare nt 29-1501 with seq. ID 3.</p> <p>---</p>	1-19
X	<p>WO 99 29725 A (CHEN FANG ;MERCK & CO INC (US)) 17 June 1999 (1999-06-17) compare seq. 5 (nt 15-2115) with sequence encoding nNR5 (nt 72-2172)</p> <p>---</p>	1-19
P,X	<p>DATABASE EMBL SEQUENCES [Online] Accession No. HSA276674, 24 March 2000 (2000-03-24) RENDTORF N.: "Assignment of the photoreceptor-specific nuclear receptor (PNR) to 15q22.32-q24.1 in the Bardet-Biedl Syndrome (BBS4) region" XP002154794 the whole document</p> <p>---</p>	1-25
X	<p>DATABASE EMBL SEQUENCES [Online] Accession No. HSAA77611, HILLIER L.: "NT2 neuronal precursor 937230, H. sapiens cDNA clone IMAGE:613508" XP002154795 compare seq. 7 with nt 125-334</p> <p>---</p>	1-19
X	<p>DATABASE EMBL SEQUENCES [Online] Accession No. 095966, 1 May 1999 (1999-05-01) ZENDMAN A.J.W.: "TM7XN1, a novel human EGF-TM7 like protein, detected with mRNA differential display using human melanoma cell lines with different metastatic potential." XP002154796 compare seq. 9 with aa 176-687 of TM7XN1.</p> <p>---</p>	1-19
A	<p>WO 99 19489 A (ADAMS ARWEN ;CHIRON CORP (US); LENG SONG (US); SHEFFIELD VAL (US);) 22 April 1999 (1999-04-22) abstract examples 1-5</p> <p>---</p> <p style="text-align: center;">-/--</p>	1-25

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/17375

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HOANG E.H. ET AL.: "Cloning of a novel C-terminal kinesin (KIFC3) that maps to human chromosome 16q13-q21 and is thus a candidate gene for Bardet-Biedl syndrome." GENOMICS, vol. 52, no. 2, 1 September 1998 (1998-09-01), pages 219-222, XP000946849 cited in the application the whole document</p> <p>-----</p>	1-25

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/17375

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 22-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-25, partly

An isolated nucleic acid molecule comprising a polynucleotide encoding amino from about 1 or 2 to about 254 of Gene X (Seq. IDs 1 and 2).

Complements and homologs thereof, vectors, recombinant host cells, polypeptides and methods of production thereof, epitope-bearing portions, antibodies, diagnostic and therapeutic applications.

2. Claims: 1-25, partly

Idem as subject matter 1, but limited to PLP (Seq. IDs 3 and 4).

3. Claims: 1-25, partly

Idem as subject matter 1, but limited to PPAR (Seq. IDs 5 and 6).

4. Claims: 1-25, partly

Idem as subject matter 1, but limited to NTPL (Seq. ID 7).

5. Claims: 1-25, partly

Idem as subject matter 1, but limited to a 7-TM protein (Seq. IDs 8 and 9).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 00/17375

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0679716 A	02-11-1995	AU 8116494 A CA 2153480 A WO 9514772 A	13-06-1995 01-06-1995 01-06-1995
WO 9947669 A	23-09-1999	DE 19813839 A	23-09-1999
WO 9929725 A	17-06-1999	EP 1044219 A	18-10-2000
WO 9919489 A	22-04-1999	AU 1098699 A	03-05-1999